NCT06206278 2024-08-14Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ AdenocarcinomaLianBio LLCPhase 2 Terminated6 enrolled
NCT03773302 2024-05-08Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/TranslocationsQED Therapeutics, a BridgeBio companyPhase 3 Terminated48 enrolled 26 charts